Reaferon-Lipint

Реаферон-Липинт Drug photo

The description is actual on 01.09.2014

  • Latin name: Reaferon-Lipint
  • ATH code: L03AB05
  • Active ingredient: Interferon alpha 2b
  • Producer: Vektor-Medika closed joint stock company, Russia

Structure

Interferon alpha 2b human recombinant on 500000 ME — active ingredient is a part of one capsule of drug.

Excipients:

  • 8,01 mg — sodium chloride;
  • 4,52 mg — sodium dodecahydrate hydrophosphate;
  • 0,56 mg — sodium dihydrate dihydrophosphate;
  • 41,18 mg — a lipoida C 100;
  • 4,53 mg — cholesterol;
  • 91,34 mg — monohydrate lactoses;
  • 0,56 mg — alpha tocopherol of acetate (vitamin E);
  • 7,54 mg — silicon of dioxide colloid anhydrous.

The cover consists:

  • 2% — titanium of dioxide (E 171) and to 100% of gelatin.

Release form

Reaferon-Lipint medicine is issued in the form of gelatinous capsules with fine-crystalline powder on 500000 ME active agents.

One packaging contains 10 capsules.

Pharmacological action

Antiviral and immunomodulatory.

Pharmacodynamics and pharmacokinetics

Antiviral effect of the drug Reaferon-Lipint is connected with ability of its active agent — interferon alpha 2b actively to join in processes of a reproduction of a virus at the cellular level. Having influence on specific receptors of a cellular cover, makes intracellular changes, including also synthesis of specific enzymes (a protein kinase and an adenilatsintetaza) and cytokines which, in turn, slow down formation of RNA of a virus and virus protein.

Immunomodulatory effect of medicine is shown by strengthening of activity of macrophages and "kilerny" cells, change of quantity and quality, the made cytokines, increase of functional action of immunocompetent cells, and also modifying of secretion and products of intracellular proteins.

Indications to use

Therapy of respiratory viral diseases and flu at patients of adult age as a part of complex treatment, and also their prevention during rise in incidence and in the period of epidemics.

Contraindications

  • age of the patient less than 18 years;
  • period of pregnancy and feeding by a breast;
  • lactose intolerance, deficit of lactase, syndrome of glyukozo-galaktozny malabsorption;
  • individual hypersensitivity to interferon or other components of medicine.

With extra care:

  • the expressed miyelosupressiya;
  • renal and/or liver failure.

Side effects

During use of capsules of Reaferona-Lipint allergic reactions, and also the grippopodobny syndrome including a fever, feeling of fatigue, fever, slackness, a headache, an arthralgia, a mialgiya, loss of appetite can be shown.

Application instruction (Way and dosage)

Reaferonn-Lipint in the form of capsules it is recommended for reception by adult patients and is not suitable for children.

Medicine is intended for oral (internal) administration in 30 minutes prior to meal.

The capsule is recommended to swallow entirely and to wash down with water.

At the complicated drug Reaferon-Lipint swallowing, the application instruction allows a possibility of accurate opening of a capsule and reception of its contents with a small amount of water.

The daily dose of Reaferona-Lipint in capsules at therapy of a SARS and flu makes 1000000 ME (2 capsules on 500000 ME in days). Drug is recommended to accept in the morning and in the evening for 5 days.

Prevention of a SARS and flu is carried out in a dose 500000 ME (1 capsule) which is accepted by 2 times a week. The course of preventive use makes 30 days.

Overdose

Overdose cases were not observed by the drug Reaferon-Lipint. Aggravation of dozozavisimy side effects is theoretically possible. Therapy — symptomatic.

Interaction

The conducted researches showed ability of interferon to reduce activity of R-450 of tsitokhrom, thereby influencing a metabolism of Phenytoinum, Cimetidinum, Dipiridamolum, Diazepam, Theophylline, Warfarin, Propranolol and some tsitostatik.

Reaferon-Lipint can aggravate neurotoxic, cardiotoxic, myelotoxic action in the past of the appointed drugs or drugs applied along with it.

It is not necessary to appoint Reaferon-Lipint together with drugs which oppress TsNS, and also with immunosuppressive medicines (including parenteral and peroral corticosteroids).

Terms of sale

Without recipe.

Storage conditions

In the refrigerator at a temperature which is not exceeding 8 °C.

Period of validity

2 years.

Special instructions

At emergence of allergic manifestations during reception of Reaferona-Lipint it is necessary to see the attending physician.

Analogs

Section: Immunity increase Antiviral
in more detail

Education: Graduated from the Vinnytsia national medical university of N. I. Pirogov, pharmaceutical faculty, the higher pharmaceutical education – the specialty "Pharmacist".

Experience: Work in Koneks and Bios-Media pharmacy chains as "Druggist". Work as "Pharmacist" in Avicenna pharmacy chain of the city of Vinnytsia.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before use of Reaferon-Lipint medicine surely consult with the attending physician.